Navigation Links
Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia
Date:4/23/2013

CAMBRIDGE, England, April 23, 2013 /PRNewswire/ --

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia (PHN). Convergence is conducting the development of CNV2197944 on behalf of Calchan Ltd.

The trial is a randomised double-blind, placebo controlled, phase II study to evaluate the efficacy and safety of orally administered CNV2197944 in patients with PHN. The primary endpoint of the trial is the effect of repeat oral dosing of CNV2197944 on the pain experienced in PHN, as measured by the Pain Intensity Numeric Rating Scale (PI-NRS), after three weeks, compared to baseline. The study is expected to conclude in 1Q2014.

Post-herpetic neuralgia (PHN) is a nerve pain due to damage caused by the varicella zoster virus (Shingles or Chicken Pox). Typically, the neuralgia is confined to a dermatomic area of the skin and follows an outbreak of the virus in the same dermatomic area. Injury to sensory nerves can cause excruciating pain, sometimes persisting for months or years.

CNV2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels. Based on positive pre-clinical and clinical data already reported, it is believed that CNV2197944 will be an effective treatment for neuropathic pain with analgesic potential for a broad range of chronic pain conditions. Extensive safety and toxicology studies to support the clinical development of CNV2197944 have also been completed, which suggest an excellent margin of safety and tolerability. CNV2197944 is the only truly selective Cav2.2 blocker in clinical development and has the potential to be a first in class treatment for chronic pain.

Clive Dix , Chief Executive Officer of Convergence Pharmaceuticals, added: "We are very excited to be starting the first proof of concept trial with CNV2197944 in neuropathic pain. We strongly believe that CNV2197944 has the optimum profile for success in this neuropathic pain area, which is in real need for efficacious and safe pain treatments. CNV2197944 has the potential to have broad applications across the pain spectrum and we look forward to announcing further proof of concept trials with CNV2197944 beyond PHN."

About the pain therapeutic area

The pain therapeutic area encompasses any disease where pain is a major symptom. The unmet medical need for patients in pain is enormous, with the greatest need being for a more effective therapy that is well tolerated and safe over a long period of time. Within the pain marketplace, current pain treatments are unsatisfactory; overall efficacy is poor (typically 1-2 point reductions on a 10 point scale) and satisfactory to less than 50% of patients. Whilst treatments, such as opioids and non-steroidal anti-inflammatory drugs, are available on the market, many patients obtain little or no relief from these existing analgesics and often such drugs are associated with adverse events, side effects and addiction concerns. This highlights the importance of Convergence Pharmaceuticals' goals to be a world leader in the development of novel, efficacious analgesics with improved pharmacology and safety profiles.

About chronic pain

Currently, more than 1.5 billion people worldwide suffer from chronic pain of varying degrees. Among all types of chronic pain, neuropathic pain stands out with approximately 3-4.5% of the global population affected, with incidence rate increasing in line with increased age of the population. With the unmet clinical need so high, the demand for better pain management therapies, addressing acute and chronic pain, is on the rise.

According to recent research the global pain management market is to reach US$60 Billion by 2015.[1]

About Calchan

As part of a restructuring of Convergence in 2011, CNV2197944 was subsequently transferred into Calchan Ltd, a sister company of Convergence Pharmaceuticals in which the proprietary rights to CNV2197944 are held. Calchan Ltd is developing its own portfolio of Calcium ion channel modulators and has contracted Convergence to undertake certain development activities with CNV2197944 on its behalf.

About Convergence Pharmaceuticals

Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company, led by CEO Clive Dix , was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline ("GSK"). The Company has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signalling through modulation of specific ion-channels.

Convergence Pharmaceuticals is well funded and raised US$35.4 million in Series A financing from a syndicate of leading European and US financial institutions. For more information please go to the Company's website at http://www.convergencepharma.com

References:

1. Global Industry Analysts Inc. 2010, "Pain Management: A Global Strategic Business Report".

http://www.strategyr.com/Pain_Management_Market_Report.asp

For more information about Convergence Pharmaceuticals, please contact:

Convergence Pharmaceuticals
Dr Clive Dix , Chief Executive Officer
Dr Simon Tate , Chief Scientific Officer
T: +44-(0)-1223-755-501
E: info@convergencepharma.com

M:Communications
Mary Clark / Amber Bielecka / Hollie Vile
T: +44-(0)-20-7920-2330
E: convergence@mcomgroup.com


'/>"/>
SOURCE Convergence Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Convergence Pharmaceuticals Announces Successful Interim Data from Ground-Breaking Phase II Trigeminal Neuralgia Study
2. Eighth Annual WLSA Convergence Summit Focuses on Moving from Innovation to Adoption
3. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
4. Immune Pharmaceuticals CEO to Chair BIO International Panel "Can Israel Become the Next Biotech Startup Nation?"
5. European Nuclear Medicine / Radiopharmaceuticals Market - Global Trends & Forecasts to 2017
6. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
7. Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
8. ADial Pharmaceuticals Announces Agreement With FDA For Phase III Trial Of AD04 For Alcohol Use Disorder In Patients Of Targeted Genotypes
9. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
10. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
11. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... held the largest share in the ECG Cables And ... demand for remote monitoring ECG devices. On the other hand, ... to witness the highest growth rate during the forecast period. ... Dickinson and Company (U.S.), Medtronic plc ( Ireland ... and Mindray Medical International Limited ( China ), ...
(Date:12/2/2016)... , Dec 2, 2016 Research and Markets ... Share, Development, Growth and Demand Forecast to 2022" report to their ... , , ... $6 billion in 2015, and it is expected to grow at a ... is expected to witness faster growth during the forecast period, a CAGR ...
(Date:12/2/2016)... SAN FRANCISCO , Dec. 2, 2016  PipelineRx, ... clinical telepharmacy, will be offering demonstrations of its ... American Society of Health-System Pharmacists 2016 Midyear Clinical ... Las Vegas . With nearly 300 hospital ... telepharmacy services and technology designed to dramatically improve ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... 2016 , ... On Dec. 2, 2016, CURE® magazine will host the 4th ... 2016 MPN Heroes—eight individuals who have made a difference in the field of rare ... of care, demonstrating leadership within the MPN community and/or a commitment to individual patients. ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to change ... Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch ... plan (Part D) need to make changes during this period order for their new ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, ... standing as living proof that attitude and determination can combine into the most ... spike around the holidays. This campaign will offer patients a new-found hope, by ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
Breaking Medicine News(10 mins):